have signed definitive agreements whereby Quintiles will become a financial and strategic partner for the global clinical development of Intarcia’s ITCA 650.
Contingent upon successful development and approval, ITCA 650 would be the first and only once-yearly injection-free GLP-1 therapy for the treatment of type 2 diabetes, enabling a broader patient population to benefit from the glycemic control, weight loss and improved adherence and tolerability observed in clinical studies to date with DUROS continuous delivery of exenatide. This alliance is the first of Intarcia’s two-step plan: first, to have a development partner, Quintiles, that delivers high-quality operational excellence in running multiple phase III studies in parallel; second, to finalize and capture the global power, reach and skill of a top-tier, diabetes-focused pharmaceutical company.
Quintiles will support the accelerated development of ITCA 650 by its capital solutions group providing a combination of equity, product, and operational investments. Intarcia is currently in negotiations to select a global pharmaceutical partner to contribute funding for the clinical development and commercialization of ITCA 650.